Alphamab Oncology (stock code: 9966.HK) announced that the biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003 has been granted Fast Track Designation (FTD) by the U.S. Food and Drug ...
Ipilimumab plus nivolumab improved PFS over nivolumab alone in MSI-H/dMMR mCRC, with no new safety concerns. The combination showed higher overall response rates and a favorable safety profile ...
In breast cancer patients with a high recurrence score, the 5-year disease-free rate was significantly higher for patients receiving taxanes with anthracycline and cyclophosphamide than for those ...
Biontech Se Sponsored Adr (($BNTX)) announced an update on their ongoing clinical study. BioNTech SE, in collaboration with Genentech, Inc., is ...
TipRanks on MSN
Daiichi Sankyo’s Latest Clinical Study: A Potential Game-Changer in Esophageal Cancer Treatment
Daiichi Sankyo Company (($DSKYF)) announced an update on their ongoing clinical study. Study Overview: The study titled A Phase 1/2 Open-Label, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback